☰

Aaron M. LeBeau, Ph.D. - Publications

Affiliations: 
2009 Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Biochemistry, Oncology
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Hintz HM, Snyder KM, Wu J, Hullsiek R, Dahlvang JD, Hart GT, Walcheck B, LeBeau AM. Simultaneous engagement of tumor and stroma targeting antibodies by engineered NK-92 cells expressing CD64 controls prostate cancer growth. Cancer Immunology Research. PMID 34452926 DOI: 10.1158/2326-6066.CIR-21-0178  0.387
2020 Hintz HM, Gallant JP, Vander Griend DJ, Coleman I, Nelson PS, LeBeau AM. Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32636317 DOI: 10.1158/1078-0432.Ccr-20-1358  0.573
2019 Glumac PM, Gallant JP, Shapovalova M, Li Y, Murugan P, Gupta S, Coleman I, Nelson PS, Dehm SM, LeBeau AM. Exploitation of CD133 for the targeted imaging of lethal prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31732520 DOI: 10.1158/1078-0432.Ccr-19-1659  0.512
2019 Shapovalova M, Lee JK, Li Y, Vander Griend DJ, Coleman I, Nelson PS, Dehm SM, LeBeau AM. PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer. Cancer Research. PMID 31530569 DOI: 10.1158/0008-5472.Can-19-2181  0.574
2019 Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Correction: Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer. Oncotarget. 10: 4920. PMID 31448058 DOI: 10.18632/oncotarget.27143  0.4
2019 Hintz HM, Cowan AE, Shapovalova M, LeBeau AM. Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma. Bioconjugate Chemistry. PMID 30966746 DOI: 10.1021/Acs.Bioconjchem.9B00206  0.37
2019 Glumac P, LeBeau A. Abstract 1150: Targeted immunoPET imaging of prostate cancer using a novel CD133 antibody Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1150  0.527
2018 Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase promoter for the molecular imaging of prostate cancer. Oncotarget. 9: 36693-36704. PMID 30613352 DOI: 10.18632/Oncotarget.26401  0.566
2018 Shapovalova M, Pyper SR, Moriarity BS, LeBeau AM. The Molecular Imaging of Natural Killer Cells. Molecular Imaging. 17: 1536012118794816. PMID 30203710 DOI: 10.1177/1536012118794816  0.302
2018 Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clinical and Translational Medicine. 7: 18. PMID 29984391 DOI: 10.1186/S40169-018-0198-1  0.369
2018 Glumac PM, Forster CL, Zhou H, Murugan P, Gupta S, LeBeau AM. The identification of a novel antibody for CD133 using human antibody phage display. The Prostate. PMID 29790189 DOI: 10.1002/Pros.23656  0.416
2017 Joshi S, Chen L, Winter MB, Lin YL, Yang Y, Shapovalova M, Smith PM, Liu C, Li F, LeBeau AM. The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach. Scientific Reports. 7: 1424. PMID 28465619 DOI: 10.1038/S41598-017-01542-5  0.54
2015 Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nature Communications. 6: 8448. PMID 26423607 DOI: 10.1038/Ncomms9448  0.332
2015 LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Research. 75: 1225-35. PMID 25672980 DOI: 10.1158/0008-5472.Can-14-2185  0.617
2015 LeBeau AM, Denmeade SR. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Molecular Cancer Therapeutics. 14: 659-68. PMID 25537662 DOI: 10.1158/1535-7163.Mct-14-0744  0.721
2014 LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 4: 267-79. PMID 24505235 DOI: 10.7150/Thno.7323  0.352
2013 LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Research. 73: 2070-81. PMID 23400595 DOI: 10.1158/0008-5472.Can-12-3526  0.41
2013 LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proceedings of the National Academy of Sciences of the United States of America. 110: 93-8. PMID 23248318 DOI: 10.1073/Pnas.1218694110  0.486
2010 Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y, Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. The Journal of Biological Chemistry. 285: 26878-88. PMID 20501655 DOI: 10.1074/Jbc.M109.077677  0.33
2010 LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biological Chemistry. 391: 333-43. PMID 20180648 DOI: 10.1515/Bc.2010.044  0.69
2009 Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 77: 984-93. PMID 19705489 DOI: 10.1002/Prot.22524  0.694
2009 LeBeau AM, Banerjee SR, Pomper MG, Mease RC, Denmeade SR. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & Medicinal Chemistry. 17: 4888-93. PMID 19541487 DOI: 10.1016/J.Bmc.2009.06.012  0.707
2009 LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics. 8: 1378-86. PMID 19417147 DOI: 10.1158/1535-7163.Mct-08-1170  0.636
2009 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 48: 3490-6. PMID 19281249 DOI: 10.1021/Bi9001858  0.693
2008 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology. 15: 665-74. PMID 18635003 DOI: 10.1016/J.Chembiol.2008.05.020  0.712
2005 Zheng W, Schwarzer D, Lebeau A, Weller JL, Klein DC, Cole PA. Cellular stability of serotonin N-acetyltransferase conferred by phosphonodifluoromethylene alanine (Pfa) substitution for Ser-205. The Journal of Biological Chemistry. 280: 10462-7. PMID 15632116 DOI: 10.1074/Jbc.M412283200  0.35
Show low-probability matches.